2021
DOI: 10.5070/d3271052044
|View full text |Cite
|
Sign up to set email alerts
|

Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
34
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(34 citation statements)
references
References 4 publications
0
34
0
Order By: Relevance
“…Recurrence occurred in 16% of those who experienced the first reaction. Exanthema reactions can be easily treated with systemic and/or topical corticosteroid and systemic antihistamines to relieve symptoms and shorten the disease duration [20,21]. We also observed the occurrence of uncommon rashes as SDRIFE (Figure 4).…”
Section: Exanthemasmentioning
confidence: 66%
See 2 more Smart Citations
“…Recurrence occurred in 16% of those who experienced the first reaction. Exanthema reactions can be easily treated with systemic and/or topical corticosteroid and systemic antihistamines to relieve symptoms and shorten the disease duration [20,21]. We also observed the occurrence of uncommon rashes as SDRIFE (Figure 4).…”
Section: Exanthemasmentioning
confidence: 66%
“…Exanthemas (morbilliform or maculopapular, varicella-like, or papulovesicular); vascular lesions (purpura/petechiae, livedoid, and chilblain-like); and urticarial are morphological patterns that are already associated with SARS-CoV-2 infection [79]. Hence, common immunopathological mechanisms, including host immune activation against viral particles, rather than direct viral damage, may be involved [6,7,21]. Polyethylene glycol-2000 (PEG) and polysorbate 80 are the two main potential allergenic/immunogenic excipients in the COVID-19 vaccines.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, polymorphic exanthemas in connection with viral infections, drugs, or both may be specified as rash if a further description is added (e.g., morbilliform-"like an exanthema seen with measles"). Normally, paraviral exanthemas and maculopapular drug eruptions develop within one week, and are self-limiting; the same seems to be true for rashes associated with COVID-19 vaccines, assuming a correct diagnosis in the published data [21,55]. On the other hand, there are reports about very early onset of rashes-within hours-which then persist as pruritic eruptions over weeks [56].…”
Section: Maculopapular Morbilliform and Vesicular Rashmentioning
confidence: 94%
“…Since December 2020, different types of COVID-19 vaccines have been developed to limit the spread of the pandemic [Jedlowski et al, 2021]. There are few reported side effects and adverse reactions of COVID-19 vaccines.…”
mentioning
confidence: 99%